Presatovir - Gilead Sciences

Drug Profile

Presatovir - Gilead Sciences

Alternative Names: GS-5806

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Amines; Antivirals; Chlorophenols; Piperidines; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 27 Sep 2017 Gilead Sciences completes a phase II trial for Respiratory syncytial virus infections (In adults, In the elderly) in USA, Belgium, Canada, Australia, France, Germany, Netherlands and United Kingdom (PO) (NCT02534350)
  • 31 Aug 2017 Phase-II development for Respiratory syncytial virus infections (In adults, In the elderly) is ongoing in countries worldwide (PO) (Gilead Sciences pipeline, August 2017)
  • 14 Jul 2017 Gilead Sciences completes a phase II trial in Respiratory syncytial virus infections (In the elderly, In adults) in USA, Australia, France, Germany, South Korea, Netherlands, Singapore, Spain, Sweden, Switzerland, United Kingdom, Brazil, Canada, Israel and Taiwan (PO) (NCT02254408)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top